Clinical Trial Update: A Study of SGT-212 Gene Therapy in Friedreich's Ataxia [Phase 1]

View source ↗

Summary

A Phase 1 study of SGT-212 gene therapy for Friedreich's ataxia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• SGT-212

Snippet

Sponsor: Solid Biosciences Inc. | Conditions: Friedreich's Ataxia (FA) | Phase 1 | Status: RECRUITING